Shares of DiaMedica Therapeutics Inc. (DMAC) touched a 52-week high of $6.41 last week, driven by investor optimism following the recent key updates on its clinical pipeline, including the ReMEDy2 trial for acute ischemic stroke and the Phase 2 preeclampsia study.
The clinical-stage biopharmaceutical company is advancing its lead candidate, DM199, a recombinant form of human tissue kallikrein-1 (rhKLK1), in trials for both acute ischemic stroke and preeclampsia.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com